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A B S T R A C T
Background
Pneumonia is a leading cause of morbidity and mortality in children younger than five years of age. Most deaths occur during infancy
and in low-income countries. Daily zinc supplements have been reported to prevent acute lower respiratory tract infection (LRTI) and
reduce child mortality. This is an update of a review first published in 2010.
Objectives
To evaluate the effectiveness of zinc supplementation in the prevention of pneumonia in children aged two to 59 months.
Search methods
We searched CENTRAL (Issue 21 October 2016), MEDLINE (1966 to October 2016), Embase (1974 to October 2016), LILACS
(1982 to October 2016), CINAHL (1981 to October 2016), Web of Science (1985 to October 2016) and IMSEAR (1980 to October
2016).
Selection criteria
Randomised controlled trials (RCTs) evaluating zinc supplementation for the prevention of pneumonia in children aged from 2months
to 59 months.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data.
Main results
We did not identify any new studies for inclusion in this update. We included six studies that involved 5193 participants.
Analysis showed that zinc supplementation reduced the incidence of pneumonia by 13% (fixed-effect risk ratio (RR) 0.87; 95%
confidence interval (CI) 0.81 to 0.94, six studies, low-quality evidence) and prevalence of pneumonia by 41% (random-effects RR
0.59; 95% CI 0.35 to 0.99, one study, n = 609, low-quality evidence). On subgroup analysis, we found that zinc reduced the incidence
of pneumonia defined by specific clinical criteria by 21% (i.e. confirmation by chest examination or chest radiograph) (fixed-effect RR
0.79; 95% CI 0.71 to 0.88, four studies, n = 3261), but had no effect on lower specificity pneumonia case definition (i.e. age-specific
fast breathing with or without lower chest indrawing) (fixed-effect RR 0.95; 95% CI 0.86 to 1.06, four studies, n = 1932).
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Authors’ conclusions
Zinc supplementation in children is associated with a reduction in the incidence and prevalence of pneumonia.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplementation for the prevention of pneumonia in children aged two to 59 months
Review question
We evaluated the effectiveness of zinc supplementation to prevent pneumonia in children aged from two to 59 months.
Background
Zinc is an essential element for children’s growth and development. Too little zinc is associated with increased risk of infection,
particularly diarrhoea and pneumonia. Children are more prone to zinc deficiency because they are less able to absorb dietary zinc
and some children, especially in low-income countries, may not have received enough zinc from their mothers before birth. Zinc
supplements for children has been reported to prevent pneumonia.
Search date
We searched the literature up to October 2016. This is an update of a review published in 2010. We did not find any new studies for
this update.
Study characteristics
We included six studies that investigated zinc supplements to prevent pneumonia. The studies were conducted in Bangladesh, India,
Peru and South Africa and involved 5193 children aged from two to 59 months. Children received either zinc or a similar-looking
treatment that did not contain zinc. In two studies, children were also given vitamin A.
Study funding sources
All included studies were funded. Of these, three explicitly mentioned that funding agencies had no role in the design and results of
the study.
Key results
Zinc supplementation was significantly associated with reducing the incidence and prevalence of pneumonia among children aged from
two to 59 months. On subgroup analysis, we found that a more stringent diagnosis (radiological examination) increased the reduction
in pneumonia incidence.
Quality of the evidence
Overall, evidence quality was assessed as low on GRADE assessment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Zinc supplementation compared with placebo for the prevention of pneumonia in children aged 2 months to 59 months
Patient or population: children aged 2 months to 59 months
Settings: Bangladesh, India, Peru, South Af rica
Intervention: zinc supplementat ion
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Zinc supplementation
Pneumonia incidence 343 per 1000 299 per 1000
(278 to 323)
RR 0.87
(0.81 to 0.94)
5193
(6 studies)
⊕⊕©©
low1,2
Pneumonia prevalence 22 per 1000 13 per 1000
(8 to 22)
RR 0.59
(0.35 to 0.99)
609
(1 study)
⊕⊕©©
low3,4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Studies have unclear information on allocat ion concealment, blinding and report ing biases.
2 Pneumonia diagnosis criteria was used dif ferent ly.
3 Studies have lim ited information on blinding of outcomes assessors and report ing bias.
4 Total number of events were less than 300.
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B A C K G R O U N D
Description of the condition
Pneumonia is the largest cause of childhood mortality, accounting
for 15% of all childhood deaths under five years (WHO 2015),
and 19% of all childhood deaths in low-income countries (Bryce
2005; Rudan 2008). Pneumonia is diagnosed by the presence of
either fast breathing or lower chest wall indrawing (WHO 2015)
in children aged under five years. Presenting features in viral or
bacterial pneumonia are similar, however wheezing is more com-
mon in children with viral pneumonia.
Pneumonia can be prevented by immunising againstHaemophilus
influenzae type B (Hib), pneumococcus, measles and pertussis
(whooping cough) (WHO 2015). Nutrition including breastfeed-
ing for the first six months of life plays a major role by boost-
ing immunity against causative organisms of pneumonia (WHO
2015). Good hygiene and clean indoor air also help in preventing
pneumonia (WHO 2015).
Rudan 2013 identified five risk factors for pneumonia: malnutri-
tion, low birth weight, nonexclusive breast feeding, solid fuel use
andovercrowding. By 2010, pneumonia episodes for children aged
under four years in low- and middle-income countries (LMICs)
decreased by 25% over the past decade to about 0.22 episodes per
child per year when exposure to the five risk factors decreased by
20% to 30% (Rudan 2013). Therefore, any interventions that can
improve child survival from pneumonia are important.
According to the World Health Organization (WHO), zinc de-
ficiency accounts for 13% of all lower respiratory tract infection
(LRTIs) (WHO 2009). Acute LRTI is a leading cause of mortality
among children aged under five years (Bryce 2005; Rudan 2008),
and which is responsible for nearly two million deaths annually,
mainly in low-income countries.
Description of the intervention
In 2005, zinc intake was inadequate among 17.3% of the world’s
population; rates of zinc adequacy are lower in sub-Saharan Africa
and South Asia (Wessells 2012). The World Bank described mul-
tiple factors such as low animal food intake, less bioavailability of
dietary zinc, and zinc loss during events of diarrhoea (Bhutta 1999;
Black 1998) that could potentially lead to zinc deficiency in low-
income settings (World Bank 2016). The WHO estimated that
zinc deficiency may be related to 800,000 deaths a year, with more
than 50% occurring in children under five years of age. Children
are more susceptible to zinc deficiency because of lower rates of
intestinal absorption and from starting life with low body stores
due to intrapartum under-nutrition (Krebs 2014).
Mild-to-moderate zinc deficiency is associated with impaired
physical growth, delayed sexual maturity, behavioural distur-
bances, anorexia, affected permeability of the intestinal tract and
decreased immunocompetence as well as subclinical inflamma-
tion; moderate-to-severe deficiency can lead to diarrhoea; and se-
vere deficiency produces dermatitis and alopecia (Krebs 2014).
There is evidence that preventative zinc supplementation reduces
pneumonia morbidity (Bhutta 1999; Yakoob 2011) and is bene-
ficial in reducing diarrhoeal episodes in children with acute and
persistent diarrhoea (Bhandari 1994; Zinc Group 2000). How-
ever, there is insufficient evidence to support preventive zinc sup-
plementation or adjunctive zinc supplementation with antibiotics
to reduce pneumonia-specific mortality (Haider 2011; Yakoob
2011). Zinc supplements (zinc sulphate, zinc gluconate, zinc ac-
etate) can be administered as tablets, syrup or powder. However,
zinc supplements need to be administered with caution because
excess levels may cause toxicity.
How the intervention might work
Zinc plays an important role in cell regeneration, immunity and
growth (Krebs 2014; Shankar 1998). Zinc deficiency decreases
T-lymphocytes and T-helper, impairs macrophage function and
reduced killer cells (Ibs 2003; Ravaglia 2000), and adversely im-
pacts innate immunity affecting interferon (IFN) gamma produc-
tion, interleukin-2 (IL-2) and tumour necrosis factor-α (TNF-α)
(Krebs 2014). Zinc supplementation in children increases levels
of complement in the blood that modulate the function of T-
lymphocytes, T-helper, macrophages and neutrophils and hence
improves the ability to fight infection. Zinc supplementation im-
proves circulating levels of T-lymphocytes and other macrophages
that enhance ability to fight infection (Fraker 1993). Zinc is not
stored in the body, but repletion is straightforward. Children with
diarrhoea can become zinc deficient quickly. Furthermore, if zinc
deficiency occurs during periods of growth, it can be conducive to
growth faltering as is shown by a review that found correlation be-
tween dietary zinc inadequacy and stunting among children aged
under four years (Krebs 2014; Wessells 2012).
Why it is important to do this review
Bhutta 1999 showed that zinc was associated with a reduced inci-
dence of pneumonia. Aggarwal 2007 included more recent stud-
ies, but included children aged between birth and 59 months who
were given zinc supplements for at least a few months. Roth 2010
calculated the effect size by case definition of pneumonia, and
included studies that administered zinc supplements to children
aged between birth and 59 months. Yakoob 2011 focused on zinc
supplementation for more than three months in children aged un-
der five years and found evidence to support the positive impact
of zinc supplementation on diarrhoeal and pneumonia morbid-
ity and mortality to include it in the LiST tool. However Yakoob
2011 did not include low birth weight or small-for-gestational
age infants, nor provide a specific case definition for pneumonia.
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Similarly, a review by Bhutta 2013 of diarrhoea and pneumonia
interventions reported a non-significant impact of preventive zinc
supplementation on acute lower respiratory infection (ALRI)-re-
lated mortality.
We investigated zinc supplementation for at least three months in
children aged from two months to 59 months and conducted a
meta-analysis of data published up to 2011. However, with new
and upcoming trials, this review required updating.
O B J E C T I V E S
To evaluate the effectiveness of zinc supplementation in the pre-
vention of pneumonia in children aged two to 59 months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) evaluating sup-
plementation of zinc for the prevention of pneumonia in children
aged from two to 59 months. We included studies that defined an
episode of pneumonia in the following ways.
1. Reported cough or difficulty in breathing with a respiratory
rate above the WHO-defined age-specific values (respiratory rate
of 50 breaths per minute or more for children aged two to 11
months, or respiratory rate of 40 breaths per minute or more for
children aged 12 to 59 months), and either documented fever
over 38°C or chest in-drawing (WHO 1990).
2. A diagnosis of pneumonia based on chest examination by a
physician.
3. A diagnosis of pneumonia based on a chest radiograph.
We included trials published in languages other than English.
Quasi-RCTs were not eligible for inclusion.
Types of participants
We included children aged from two months to 59 months.
Types of interventions
Oral supplement containing at least theUSA’s recommended daily
allowance of zinc versus either an oral supplement without zinc
or placebo. We excluded trials in which children were given ad-
ditional supplements unless the co-interventions other than zinc
were the same in both groups. The recommended daily allowance
for infants is 5 mg of elemental zinc per day and 10 mg per day for
children aged from one to five years (RDA 1989). We included
trials in which supplements were administered for at least three
months and outcome surveillance was carried out for at least four
weeks.
Types of outcome measures
Primary outcomes
1. Numbers of new episodes of pneumonia in children aged
from two months to 59 months.
Secondary outcomes
1. Prevalence (number of cases of pneumonia at a given time
per total days of observation) of pneumonia in children aged
from two months to 59 months.
Search methods for identification of studies
Electronic searches
We searched
the Cochrane Central Register of Controlled Trials (CENTRAL),
the Cochrane Library (www.thecochranelibrary.com, accessed 21
October 2016), which contains the Acute Respiratory Infections
Group’s Specialised Register, MEDLINE (November 2009 to 21
October 2016) and Embase (January 2010 to 21 October 2016).
We searched LILACS (1982 to 21 October 2016) using a new
search strategy. We also searched CINAHL (1981 to 21 October
2016) and Web of Science (1985 to 21 October 2016). Details of
previous searches are presented in Appendix 1.
We used the search strategy described in Appendix 2 to search
MEDLINEandCENTRAL.We combined theMEDLINEsearch
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision); Ovid format (Lefebvre 2011)
. We adapted the search strategy to search Embase (Appendix
3), LILACS (Virtual Health Library) (Appendix 4), CINAHL
(Appendix 5) andWeb of Science (Appendix 6). We searched IM-
SEAR using the search terms “pneumonia” and “zinc”. We im-
posed no language or publication restrictions.
Figure 1 illustrates the search and study selection processes.
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Figure 1. Study flow diagram
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Searching other resources
We searched the WHO ICTRP (www.who.int/ictrp) and Clin-
icalTrials.gov trials registries (latest search 8 July 2016). We also
searched related conference proceedings for relevant abstracts. We
also checked the reference lists of all trials identified.
Data collection and analysis
Selection of studies
Two review authors independently assessed all potential studies
identified for inclusion. We resolved any disagreement through
discussion, and if required, consulted the third review author.
Data extraction and management
We designed a data extraction form. Two review authors extracted
data. We resolved discrepancies through discussion, and if re-
quired, we consulted the third review author.We entered data into
Review Manager software (RevMan 2014) and checked for accu-
racy. There were no new studies identified for inclusion in this
update.
Assessment of risk of bias in included studies
There were no new studies identified for inclusion for this update.
For the 2010 version of this review (Lassi 2010), two review au-
thors (ZSL, BAH) independently assessed risk of bias using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We resolved any disagreement by
discussion with the third review author (ZAB).
Measures of treatment effect
For dichotomous outcomes, we extracted the total number of par-
ticipants for each group and numbers of participants experiencing
an event. We used risk ratio (RR) and 95% confidence intervals
(CIs) to describe effect sizes.
Unit of analysis issues
We carried out statistical analysis using RevMan 2014). Initially,
we used fixed-effect inverse variancemeta-analysis to combine data
where trials examined the same intervention, and study popula-
tions and methods were judged sufficiently similar. Where we sus-
pected clinical or methodological heterogeneity between studies
sufficient to suggest that treatment effects may differ between tri-
als, we conducted random-effects meta-analysis. When we iden-
tified substantial heterogeneity in a fixed-effect meta-analysis, we
noted this and repeated the analysis using the random-effects
method.
Dealing with missing data
We noted levels of attrition among included studies. As far as
possible, we performed analyses on an intention-to-treat (ITT)
basis. We attempted to include all participants randomised to each
group in the analyses.
Assessment of heterogeneity
We measured heterogeneity among the trials by calculating the I²
statistic, and Chi² P value. If the I² statistic exceeded 50%, and
the Chi² P value was less than 0.1, we would have considered het-
erogeneity to be substantial. We did not find any heterogeneity;
therefore, we did not attempt subgroup analyses based on differ-
ences in zinc dosage, participants’ age, supplementation in healthy
children compared with children recovering from an episode of
illness, and pre-intervention zinc levels. However, we attempted
to look for the differential effect of zinc supplementation on the
case definition of ALRI.
Assessment of reporting biases
We aimed to assess reporting bias by comparing published study
reports with study protocols. We planned to assess for the presence
of publication bias by looking for funnel plot asymmetry; however,
the low number of included studies meant this was not feasible.
Data synthesis
We carried out statistical analysis using RevMan 2014 software. In
the absence of significant heterogeneity, we used the fixed-effect
meta-analysis model for combining data.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis based on diagnosis of
pneumonia.
Sensitivity analysis
Weplanned to carry out a sensitivity analysis to explore the effect of
trial quality (assessed by concealment of allocation), by excluding
studies with clearly inadequate allocation concealment. However,
only two studies had adequate allocation concealment, therefore
we did not run the sensitivity analysis.
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R E S U L T S
Description of studies
SeeCharacteristics of included studies, Table 1 and Characteristics
of excluded studies tables.
Results of the search
This is an update of a review previously published in 2010 (Lassi
2010). The most recent search (to October 2016) did not identify
any new studies for inclusion.
Included studies
We included six trials. These studieswere fromBangladesh (Brooks
2005), India (Bhandari 2002; Sazawal 1998), Peru (Penny 2004),
and South Africa (Bobat 2005; Luabeya 2007).
Penny 2004 conducted a randomised, double-blind, placebo-con-
trolled community-based trial in Lima, Peru that involved 238
childrenwith diarrhoea for more than 14 days whowere aged from
six to 36 months. Children were randomised to receive zinc alone,
zinc plus vitamins or placebo for two weeks. Childrens’ character-
istics at baseline were similar except for sex and length-for-age Z
scores.
Brooks 2005 conducted a study in a low-income population in
an urban setting of Dhaka, Bangladesh. The study included 1665
children aged from 60 days to 12 months who were randomly
allocated to receive oral zinc (70 mg) or placebo once weekly.
Children were assessed weekly in the children’s homes. Children
with suggestive respiratory disease or diarrhoea were referred to
clinics where they were assessed and diagnoses made based on the
WHO criteria.
Bhandari 2002 included 2482 children aged six to 30months who
were from urban slums in New Delhi, India. Children received
daily elemental zinc (10mg for infants; 20mg for older children) or
placebo for four months. Both groups received single dose vitamin
A (100,000 IU for infants and 200,000 IU for older children) at
enrolment. Both groups were comparable on socio-demographic
profile, anthropometry, child feeding practices, morbidity in the
previous 24 hours, and plasma zinc concentration.
Luabeya 2007 included children aged from four to six months
from the KwaZulu-Natal Province of South Africa. Children were
randomised to two intervention arms and one control arm. Chil-
dren in the control arm received vitamin A only; in the first in-
tervention arm they were given vitamin A plus zinc; and in the
second intervention arm children received vitamin A, zinc and
multiple micronutrients. Children received supplements until 24
months of age, thus each child received zinc supplements for 18 to
20 months. Among the participants, 32 children were born with
HIV positive status, and 154 were born without HIV infection
to HIV positive mothers. Groups differed on weight-for-length
scores.
The double-blind controlled trial by Sazawal 1998 was conducted
in a low socioeconomic population of 609 children aged between
six and 35 months in urban India. Children were assigned to
zinc supplementation (n = 298) and placebo (n = 311) groups.
Children in the treatment group received 10 mg elemental zinc
and placebo group children received a substance similar in colour
and taste. The daily fixed dose of 5 mL per child was given to all
enrolled children for six months, but this was increased to 10 mL
for children with diarrhoeal illnesses. The baseline characteristics
of included children were similar for age, sex, nutritional status
and baseline plasma zinc.
Bobat 2005 conducted a randomised, double-blind, placebo-con-
trolled equivalence trial of zinc supplementation at Grey’s Hospi-
tal in Pietermaritzburg, South Africa. The study included 96 chil-
dren aged from six to 60 months with HIV 1 infection who were
randomly assigned to receive 10 mg of elemental zinc sulphate or
placebo daily for six months. Baseline characteristics of included
children were similar.
Excluded studies
We excluded 30 studies that did not satisfy inclusion criteria. Seven
studies included children outside the age limits of our review cri-
teria (Lira 1998; McDonald 2015; Osendarp 2002; Sur 2003;
Taneja 2009; Tielsch 2007 (also reported a different response to
intervention definition than we used); Vakili 2009). We excluded
seven studies that provided supplements for less than threemonths
(Baqui 2002; Castillo-Duran 1987; Chandyo 2010; Feiken 2014;
Rahman 2001; Roy 1999; Sempértegui 1996). We excluded 14
studies that applied different case definitions for ALRI/pneumo-
nia, which were not based on WHO criteria, radiograph or chest
examination by physician (Baqui 2003; Larson 2010; Long 2006;
Lind 2004;Malik 2014;Mazoomar 2010; Ninh 1996; Reul 1997;
Richard 2006; Sampaio 2013; Sanchez 2014; Soofi 2013; Rosado
1997; Umeta 2000). We excluded one study because children re-
ceived zinc supplement in a fortified drink (Bates 1993). We also
excluded one study (Adhikari 2016) because it had included chil-
dren with recurrent infections.
Please refer to Characteristics of excluded studies for further de-
tails.
Risk of bias in included studies
Figure 2 and Figure 3 provide graphical summaries of the ’Risk of
bias’ assessment for the six included studies. With one exception
(Penny 2004), studies were assessed as providing low or unclear
risk of bias in relation to methods. Luabeya 2007 had the lowest
risk of bias; Penny 2004 was assessed at unclear risk of bias.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study
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Allocation
Most included studies were assessed as demonstrating adequate se-
quence generation and used computer-generated sequencing tech-
niques (Bhandari 2002; Bobat 2005; Brooks 2005; Luabeya 2007;
Sazawal 1998). Allocation concealment was adequate three studies
(Bhandari 2002; Luabeya 2007; Sazawal 1998); the remainder did
not report in sufficient detail to enable assessment (Bobat 2005;
Brooks 2005; Penny 2004).
Blinding
Blinding of participants and study personnel was achieved in four
studies (Bobat 2005; Brooks 2005; Luabeya 2007; Sazawal 1998).
The remaining studies reported insufficient information to permit
judgement (Bhandari 2002; Penny 2004).
Blinding of outcome assessors was achieved in Brooks 2005 and
Luabeya 2007. Brooks 2005 reported that blinding was not af-
fected because a proportion of children in both the zinc and
placebo groups reacted to the taste such that treatment could not
be distinguished; Luabeya 2007 reported that outcomes assessors
were blinded to assignment.
Incomplete outcome data
Attrition and exclusions were described in all except studies Penny
2004 and Sazawal 1998. The other four studies (Bhandari 2002;
Bobat 2005; Brooks 2005; Luabeya 2007) reported reasons for
exclusions; these included refusal to participate, moved outside
the study site, taste of the syrup, and death.
Selective reporting
Only Luabeya 2007 was registered with a trials register. None of
the other studies had published protocols (Bhandari 2002; Bobat
2005; Brooks 2005; Penny 2004; Sazawal 1998). However, all
proposed outcomes were reported.
Other potential sources of bias
The funding agencies were reported to have had no input to de-
sign or study results in three studies (Bobat 2005; Brooks 2005;
Luabeya 2007). Bhandari 2002; Penny 2004 and Sazawal 1998
did not mention the role of funding agencies explicitly.
Effects of interventions
See: Summary of findings for the main comparison Zinc
supplementation compared with placebo for the prevention of
pneumonia in children aged 2 months to 59 months
All six studies reported the incidence of pneumonia (Bhandari
2002; Bobat 2005; Brooks 2005; Luabeya 2007; Penny 2004;
Sazawal 1998), while one study (Sazawal 1998) also reported
prevalence rates.
Incidence of pneumonia
Administration of zinc supplementation showed a statistically sig-
nificant impact on reducing pneumonia incidence by 13% (risk ra-
tio (RR) 0.87, 95% confidence interval (CI) 0.81 to 0.94, fixed-ef-
fect model, six studies, n = 5193, low-quality evidence). There was
no heterogeneity (I² statistic = 28%, Chi² test P = 0.20; Analysis
1.1).
We pooled studies that used similar case definitions. Studies that
used clinical definitions of age-specific fast-breathing, with or
without lower chest indrawing did not exhibit impact from zinc
supplementation on reducing pneumonia (RR 0.95, 95%CI 0.86
to 1.06, fixed-effect model, four studies, n = 1932). There was no
heterogeneity (I² statistic = 0%, Chi² test P = 0.74).
Studies that applied case definition for pneumonia based on chest
examination or chest radiograph exhibited significant impact from
zinc supplementation on reducing incidence of pneumonia by
21% (RR 0.79, 95% CI 0.71 to 0.88, fixed-effect model, four
studies, n = 3261). There was no heterogeneity (I² statistic = 0%,
Chi² test P =0.44). Bobat 2005 included childrenwithHIV.When
this study was removed from the analysis there was no difference
in results (RR 0.88, 95%CI 0.81 to 0.95, fixed-effectmodel, three
studies, n = 3165). Evidence was low quality (Summary of findings
for the main comparison).
Prevalence of pneumonia
Administration of zinc supplementation showed a statistically sig-
nificant impact on reducing the pneumonia prevalence by 41%
among children aged from two to 59 months (RR 0.59, 95% CI
0.35 to 0.99, fixed-effect model, one study, n = 609, low-qual-
ity evidence; Analysis 1.2). (Summary of findings for the main
comparison).
D I S C U S S I O N
Summary of main results
This is an update of a review first published in 2010 and included
no new studies. Previous conclusions are unchanged.
We included six randomised controlled trials (RCTs) evaluating
the impact of zinc supplementation in children aged from two to
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59 months. Our meta-analysis indicated that zinc supplementa-
tion led to reductions in the incidence of pneumonia by 13% and
pneumonia prevalence by 41%. The greater overall reduction of
pneumonia prevalence result is due to prevalence data originating
from one study.
We found that zinc reduced pneumonia incidence (defined by
specific clinical criteria and confirmed by chest examination or
chest radiograph) by 21%. We found an expected association of
acute lower respiratory infection (ALRI) case definition with an
effect size (P = 0.02). We found benefits of zinc supplementation
when ALRI was diagnosed following clinical examination or chest
radiography suggesting infection.
Reduction in pneumonia incidence supports the use of zinc sup-
plements among children two to 59 months of age. Because zinc is
not stored in the body, adequate zinc needs to be available in daily
diet (Sanstead 1995). Children, particularly those from low-in-
come countries who have inadequate intake of food that contains
zinc (mainly foods of animal origin) should receive supplements
to address deficiency.
Overall completeness and applicability of
evidence
Our findings from can be extrapolated for children living in
low- and middle-income countries because most included stud-
ies were from disadvantaged urban areas of low-income countries
(Bangladesh, India, Peru, and South Africa). In two studies, either
children or their mothers had HIV positive status (Bobat 2005;
Luabeya 2007). Inmost studies, childrenwere excluded if they had
co-morbidities such as tuberculosis, congenital heart disease, less
than 60%medianweight-for-age Z score, and nutritional oedema.
Penny 2004 recruited children on their breastfeeding status. The
use of consistent and accurate definitions of pneumonia, with em-
phasis on clinical documentation of key signs or radiographic di-
agnosis, would avoid misclassification and lead to greater confi-
dence in study findings.
Quality of the evidence
We assessed that review outcomes were low according to GRADE
criteria. We downgraded evidence quality because outcomes were
ascertained using different criteria and ’Risk of bias’ assessment.Of
note, half of the included studies reported pneumonia according
to the WHO definition (WHO 1990); the remainder relied on
clinical examination and chest radiographs. We therefore looked
for differential effects on outcome estimates with respect to case
definition and reported their impact separately.
Allocation concealment was adequately described overall. All in-
cluded studies were deemed to be adequately blinded for treat-
ment assignment. Completion rates were greater than 90% in four
included studies; Penny 2004 reported completion by 16% of par-
ticipants and Sazawal 1998 did not report numbers of participants
who dropped out. The low levels of missing data meant that we
chose not to assess the impact on overall estimates because it was
not anticipated to cause significant bias in the study results.
Potential biases in the review process
We undertook a systematic search of the literature to identify all
studies that met our inclusion criteria. Study selection and data
extraction decisions were cross-checked independently by the re-
view authors. Included studies were not free from bias; only one
study was assessed at low risk of bias for all domains. We could not
assess reporting bias because of the limited numbers of included
studies.
Agreements and disagreements with other
studies or reviews
We found RCT evidence from both high- and low-income coun-
tries showing an effect of zinc in decreasing morbidity and mortal-
ity in children due to respiratory and gastro-intestinal infections
(Hambidge 1999; Sazawal 1998). The effect of zinc against infec-
tious diseases is therapeutic as well as preventive.
Findings reported by the Zinc Investigators’ Collaborative Group
in (Bhutta 1999) and Aggarwal 2007 were consistent with our
review. Bhutta 1999 reported that children who received zinc sup-
plements had positive effects for pneumonia (odds ratio (OR)
0.59, 95% CI 0.41 to 0.83). Moreover, Bhutta 1999 included
trials that administered zinc supplements with therapeutic intent,
whichmight have led to an overestimation of the potential preven-
tive effects of zinc. Aggarwal 2007 included trials that recruited
children aged from birth to 59 months who were provided zinc
supplementation for at least three months; analysis showed 20%
decreased incidence of respiratory illness among children supple-
mented with zinc compared with placebo. Similar findings were
reported by Roth 2010 who also assessed specific case definitions
for impact evaluation of children aged from birth to five years.
Roth 2010 reported that zinc reduced ALRI incidence defined by
specific clinical criteria (incidence rate ratio (IRR) 0.65, 95% CI
0.52 to 0.82), compared with no effect on lower-specificity ALRI
case definitions based on caregiver reports (IRR 1.01, 95% CI
0.91 to 1.12) or WHO non-severe pneumonia (IRR 0.96, 95%
CI 0.86 to 1.08).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found sufficient evidence to support the use of zinc supple-
mentation for children aged from two to 59 months to prevent
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pneumonia. Our analysis supports use of preventive zinc supple-
mentation to improve child health.
Implications for research
More well-designed, large-scale randomised controlled trials
(RCTs) are needed to establish the benefit of zinc supplementa-
tion for preventing pneumonia among children aged from two to
59 months. Development of effective and feasible interventions
to improve zinc status in children is essential. Enhancement of
bioavailable zinc in foods by genetic engineering, plant breeding
and periodical supplementation are other possible intervention
strategies that should be evaluated.
Given the rising burden of child mortality due to respiratory in-
fections, particularly pneumonia, and considering its decreasing
impact with zinc supplementation, further reviews should be con-
sidered in which the effectiveness of zinc supplementation should
be assessed for acute pneumonia provided that cases are well-de-
fined by strict clinical criteria.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bhandari 2002
Methods RCT in which the children were individually randomised by a computer-generated
simple randomisation scheme in blocks of 8. Zinc or placebo bottles were labelled with a
unique child identification number according to the randomisation scheme. Six bottles,
one for each month and two extra, for each child were produced and labelled before
enrolment commenced.The supplies for each childwere kept separately in labelled plastic
bags. The zinc and placebo syrups were similar in appearance, taste, and packaging.
Blinding was maintained during analyses by coding the groups as A or B
The study took place in the urban slumofDakshinpuri inNewDelhi, India. For episodes
to be counted as individual, there had to be at least 14 intervening days. The children in
the two groups were comparable for age, anthropometry, child feeding practices, mor-
bidity in the previous 24 hours, socioeconomic characteristics and plasma zinc concen-
tration
Participants The study included children aged from 6 to 30 months. There were 1241 children in
each group, and after dropouts, the number reduced to 1093 in the zinc and 1133 in the
placebo groups. Children were excluded if consent was refused, were likely to move out
of the study area within the next four months, needed urgent admission to hospital on
the enrolment day or had received a massive dose of vitamin A (100,000 IU for infants
and 200,000 IU for older children) within the two months before enrolment
Interventions Doses of elemental zinc were 10 mg for infants and 20 mg for older children (twice
the recommended daily dosage) as zinc gluconate. Zinc or placebo was taken daily for
four months. Both groups received single massive doses of vitamin A (100,000 IU for
infants and 200,000 IU for older children) at enrolment. Immunisations and treatment
for acute illnesses were provided as per WHO guidelines. Children with acute lower
respiratory tract infections received cotrimoxazole. Amoxicillin was substituted if the
child did not respond within three days. Children were sent to hospital if they had signs
and symptoms that warranted referral according to WHO guidelines
Outcomes Incidence of ALRI
ALRIs were defined by cough and fast breathing or lower chest indrawing as assessed
by the physician; other clinical signs were not taken into account. Fast breathing was
defined as 2 counts of > 50 breaths/minute for infants and > 40 breaths/minute for older
children
Pneumonia was diagnosed either by a combination of cough with crepitations or
bronchial breathing by auscultation or as an episode of ALRI associated with at least
one of lower chest indrawing, convulsions, not able to drink or feed, extreme lethargy,
restlessness or irritability, nasal flaring, or abnormal sleepiness
Notes Funding: European Union (Contract No IC18CT960045), Norwegian Council of Uni-
versities’ Committee for Development Research and Education (PRO 53/96), Depart-
ment of Child and Adolescent Health and Development (CAH), WHO
Risk of bias
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Bhandari 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “children were individually ran-
domised by a simple randomisation scheme
in blocks of eight. The randomisation
scheme was generated by a statistician at
Statens Serum Institut, not otherwise in-
volved with this study, using the SAS soft-
ware”
Allocation concealment (selection bias) Low risk Quote: “zinc or placebo syrups were pre-
pared and packaged in unbreakable bottles
by GK Pharma ApS Koge, Denmark, who
also labelled bottles with a unique child
identificationnumber according to the ran-
domisation scheme. The supplies of each
child were kept separately in labelled plas-
tic bags. The zinc and placebo were similar
in appearances, taste and packaging. Mask-
ing was maintained during the analysis by
coding the groups as A and B”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the supplies for each child were
kept separately in labelled plastic bags”.
“Masking was maintained during analyses
by coding the groups as A or B”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judg-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusion (35%) with their reasons doc-
umented. Attrition was 12% in the zinc
group and 8.7% in the control group. Loss
to follow-ups were mainly because they
refused further participation, moved and
died (3 died in the placebo group only)
Selective reporting (reporting bias) Low risk We could not locate the protocol of this
study. We could not find the trial registra-
tion number of the study. The outcomes
mentioned in the methods were reported
in the results
Other bias Unclear risk Sources of funding: Not mentioned if they
had any role in design or results of study
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Bobat 2005
Methods Randomised, double-blind, placebo-controlled trial conducted in Grey’s Hospital in
Pietermaritburg, South Africa. Baseline measurements of plasma HIV-1 viral load and
the percentage of CD4T lymphocytes were established at two study visits before ran-
domisation, and measurements were repeated 3, 6, and 9 months after the start of sup-
plementation
Participants 96 children with HIV-1 infection between the ages of 6 months and 60 months, being
cared for as outpatients at Grey’s Hospital, and not receiving anti-retroviral therapy were
recruited. Pneumonia was diagnosed by history and physical examination, including
chest auscultation, and confirmed by chest radiograph
Interventions Children either received 10 mg of elemental zinc as sulphate or placebo every day for 6
months. The child’s parent or guardian was given one packet at the first two visits and
two packets at each monthly follow-up visit thereafter, and was instructed on how to
give the tablet
Outcomes The primary outcomemeasure was plasmaHIV-1 viral load and incidence of pneumonia
Notes Outpatient management of children with HIV-1 infection is provided by a team of
paediatricians, medical officers, and nurses who care for about 20 to 30 children per
week. After starting zinc or placebo, children were assessed at Grey’s Hospital every 2
weeks for the first month, monthly for 5 months, and a final visit 9 months after zinc
or placebo supplementation started. Pneumonia was diagnosed by history and physical
examination, including chest auscultation, and confirmed by chest radiograph
Funding: This study was funded by the Johns Hopkins Family Health and Child Survival
Cooperative Agreement with the Office of Health, Infectious Diseases, and Nutrition,
Global Health Bureau, US Agency for International Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Children were block-randomised
in three age strata (6 to 23, 24 to 41, and
42 to 60 months)”; “Randomisation lists
were computer generated at the WHO in
a fixed block size of eight”
Allocation concealment (selection bias) Unclear risk Quote: “Tablets of zinc sulphate or placebo
were produced by the same manufacturer
(Nutriset, Bierne, France) and supplied in
blister packets of 14 dispersible tablets”;
“An investigator atGrey’sHospital assigned
children to the treatment groups. The in-
vestigators were unaware of the treatment
allocation until follow up was completed”
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Bobat 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “An investigator at Grey’s Hospital
assigned children to the treatment groups.
The investigatorswere unaware of the treat-
ment allocation until follow up was com-
pleted.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/105 participants (8.6%) were excluded.
2/46 (4.4%) and 9/50 (18%) participants
did not complete the trial in zinc and
placebo groups, respectively. The reasons
for lost to follow-up were mainly deaths
and refused to participate
Selective reporting (reporting bias) Low risk We could not locate the protocol of this
study. We could not find the trial registra-
tion number of the study. The outcomes
mentioned in the methods were reported
in the results
Other bias Low risk Sources of funding: funding agencies had
no role in views and opinions mentioned
in the study
Brooks 2005
Methods RCT in which random assignment to zinc or placebo was done with permuted blocks of
variable length between 2 and 8. Placebo was designed to be identical to the zinc syrup in
colour, odour, and taste. The study was conducted at Kamalapur, southeastern Dhaka,
Bangladesh. The medical officer diagnosed pneumonia if crepitations were heard on
inspiration with a respiratory rate greater than 50 breaths per minute; severe pneumonia
was diagnosed if there was also chest indrawing, or at least one other danger sign
Participants Children aged 60 days to 12 months at the time of enrolment and excluded those with
knownor suspected tuberculosis, chronic respiratory or congenital heart disease, or severe
malnutrition requiringhospital admission. Pneumoniawas diagnosed if crepitationswere
heard on inspiration with a respiratory rate greater than 50 breaths per minute; severe
pneumonia was diagnosed if there was also chest indrawing, or at least one other danger
sign. Children with wheezing or rhonchi with crepitations were also diagnosed with
pneumonia. 809 children were randomly assigned to zinc and 812 to placebo. There
were no significant differences between groups at baseline, except for a slightly higher
proportion of boys in the zinc group. There was no difference between the groups in
serum zinc values at baseline
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Brooks 2005 (Continued)
Interventions Zinc was given orally as a syrup (35 mg zinc acetate per 5 mL). The placebo was non-
nutritious and vitamin-free. Compliance required intake of two teaspoons of syrup (10
mL). Children with pneumonia were treated with co-trimoxazole (10 mg/kg trimetho-
prim, twice daily for 5 days) for pneumonia. Children on antibiotics were assessed within
72 hours of starting treatment; those who did not improve (i.e. the respiratory rate did
not change by more than 5 breaths/minute from baseline) were switched to treatment
with amoxicillin (40 mg/kg, three times daily for 5 days). If oral treatment failed, or if
they had severe pneumonia, children were referred to hospital for parenteral treatment
(ceftriaxone 75 mg/kg intramuscularly per day). Children with only expiratory wheezes
or rhonchi were managed with salbutamol syrup (0.3 mg/kg, 3 times daily), or referred
to hospital for danger signs
Outcomes Pneumonia incidence. Other outcomes included frequency of other illnesses and mor-
tality
Notes Sources of funding: The researchwas funded by JohnsHopkins Family Health and Child
Survival Cooperative Agreement with the US Agency for International Development,
the Swiss Development Corporation, and a cooperative agreement between the US
Agency for International Development (HRN-A-00-96-90005-00) and core donors to
the Centre for Health and Population Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random assignment to zinc or
placebo was done with permuted blocks of
variable length between two and eight”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “ACME Laboratories (Dhaka) pre-
pared, labelled and masked the identity
of both preparations. Both placebo and
treatment were designed to be identical in
colour, odour, and taste”; “identity of both
the preparations were masked”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Blinding of FRAs was not affected
because a proportion of children in both
zinc and placebo groups reacted to the taste
such that the treatment could not be dis-
tinguished”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was 9.1%. Withdrawal
from both groups was most commonly at-
tributed to the child’s reaction to the taste
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Brooks 2005 (Continued)
of the syrup, which sometimes resulted in
regurgitation. Most of those who withdrew
were young, primarily breast fed infants.
The highest proportion (37·1%) of with-
drawals for both groups occurred at age
2 months, with 77·1% younger than 6
months
Selective reporting (reporting bias) Low risk We could not locate the protocol of this
study. We could not find the trial registra-
tion number of the study. The outcomes
mentioned in the methods were reported
in the results
Other bias Low risk Study seems to be free from other biases;
the funding sources had no role in the study
design, data collection, data analysis, inter-
pretation of results, or decision to publish
this research
Funding: The research was funded by
Johns Hopkins Family Health and Child
Survival Cooperative Agreement with the
US Agency for International Develop-
ment, the Swiss Development Corpora-
tion, and a cooperative agreement between
the US Agency for International Develop-
ment (HRN-A-00-96-90005-00) and core
donors to the Centre for Health and Pop-
ulation Research
Luabeya 2007
Methods What was the study design?
The study was conducted in northern KwaZulu-Natal Province, South Africa. Children
were enrolled into the study by nurses at five government primary health care clinics.
Pneumonia by maternal report was considered to have occurred if there was a history
of either fast breathing or chest in-drawing. Confirmed pneumonia was defined as an
elevated respiratory rate at rest measured by the fieldworker using WHO/UNICEF
Integrated Management of Childhood Illness guidelines
Participants Add number of participants. Children eligible for study were 4 to 6months old. Children
were excluded from the study if they were: less than 60% of median weight-for-age using
United States National Center for Health Statistics standards; had nutritional oedema;
had received vitamin ormicronutrient supplements in the previousmonth; had diarrhoea
formore than seven days at the time of study enrolment; or were enrolled in another study
of a clinical intervention. Confirmed pneumonia was defined as an elevated respiratory
rate at rest measured by the fieldworker using WHO/UNICEF Integrated Management
of Childhood Illness guidelines
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Luabeya 2007 (Continued)
Interventions The 3 treatment arms were: vitamin A alone; vitamin A plus zinc; and vitamin A, zinc
and multiple micronutrients. All supplements were given daily at home from entry into
the study until 24 months of age
Outcomes Diarrhoea, pneumonia Incidence? prevalence?
Notes Funding: Supported by grants from the US National Institute of Health (1 UO1
AI45508-01, 1 K24 AI/HDO1671-01, D43TW05572-01 toDr Bennish) and theWell-
come Trust (Wellcome 62925 to Dr Bennish and Wellcome 063009 to Dr Van den
Broeck. The sponsor for the study was the host institution, the Africa Centre for Health
and Population Studies, which gave discretion in the investigative team in study design,
data analysis, manuscript preparation, and decisions on manuscript submission and pub-
lication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An allocation list was prepared us-
ing computer-generated random numbers
and a block size of six”; assignment to the
three treatment arms was done separately
for three cohorts of children stratified by
HIV status of child and mother: HIV-in-
fected children and mothers; HIV-unin-
fected children of HIV-infected mothers;
and HIV-uninfected children of HIV-un-
infected mothers
Allocation concealment (selection bias) Low risk Quote: “The manufacturer prepared num-
bered packs of tablets corresponding to
the allocation list. Children enrolled in the
study were assigned by a study physician
to one of the three study cohorts after re-
sults of theHIV tests became available. The
physician then allocated the next pack of
tablets from the blocks assigned to that co-
hort to the participant”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Investigators, study staff and par-
ticipants were blind to the treatment as-
signments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Investigators, study staff and par-
ticipants were blind to the treatment as-
signments”
24Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Luabeya 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusion (12.7%) and attrition (8.1% in
vitamin A + zinc and 8.9% in vitamin
A group) data were reported along with
their reasons. Thirty-seven children with-
drew and one died before any home visits
took place
Selective reporting (reporting bias) Low risk The study appears to be free of selective
reporting. Trial Registration
ClinicalTrials.gov NCT00156832. The
outcomes mentioned in the methods were
reported in the results
Other bias Low risk Sources of funding: The sponsor for the
study was the host institution, the Africa
Centre for Health and Population Stud-
ies, which gave discretion in the investiga-
tive team in study design, data analysis,
manuscript preparation, and decisions on
manuscript submission and publication
Penny 2004
Methods This randomised, double-blind, placebo-controlled, community-based trial was carried
out in Canto Grande, a shanty town on the outskirts of Lima, Peru. The study was
carried out in two phases. During the first phase researchers evaluated the effect of zinc
or multiple micronutrient supplementation on the recovery from persistent diarrhoea.
During the second phase researchers assessed the effect of continued supplementation
on morbidity from new infections during the following 6 months
Participants 412 children aged 6 to 36 months with diarrhoea for 14 days were randomly assigned,
after being stratified for breastfeeding status, to receive two weeks of daily supplemen-
tation with one of three indistinguishable supplements: placebo; 20 mg zinc daily as
zinc gluconate (zinc group); or 20 mg zinc daily as zinc gluconate plus a mixture of
other micronutrients, i.e. vitamins and minerals (zinc VM group). A subset of children
consisting of the first 246 children enrolled who intended to remain in the study area
subsequently received the same assigned supplement at one-half the initial daily dose (10
mg zinc daily) and continued under observation for a total of 6 months
Interventions Supplements were supplied as individual doses of a dry micronutrient mixture with
added sugar, colouring and flavouring agents, which were dissolved in clean water in
participants’ homes and provided as a liquid beverage under the supervision of study
personnel on Monday through Friday and by parents or other caregivers during the
weekends. There were two intervention arms, zinc plus vitamins and minerals who were
given 10 mg of zinc supplementation along with different combinations of mineral and
vitamins. Another interventional arm was given zinc 10 mg and the control group was
not given any supplementation
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Penny 2004 (Continued)
Outcomes Changes in plasma zinc, haematocrit, haemoglobin, plasma ferritin, pneumonia inci-
dence
Notes In this review, groups with zinc and placebo are included for analysis. Examination in-
cluded assessment of hydration status, measurement of rectal temperature and moni-
toring of respiratory rate, which was counted for 1 minute and repeated if the rate was
greater than age-specific upper limits (50/minute for children aged 6 to 11 months and
40/minute for children aged 11 months). Children were referred to the study physician
for diagnosis and treatment when the fieldworker or caregiver was concerned about the
child’s health status or if the child had any one of several predefined signs of illness,
including fever, presentation or worsening of cough with elevated respiratory rate (i.
e. fieldworker-defined acute lower respiratory infection), persistent diarrhoea, diarrhoea
with signs of dehydration, or vomiting or skin conditions requiring diagnosis
Sources of funding: Supported primarily by the Thrasher Research Fund and the World
Health Organization; additional funds were provided by the University of California
Pacific Rim Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-masked”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-masked”
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/81 (17.3%) in zinc and 13/83 (15.7%)
placebo groups lost to follow-up but no rea-
sons were reported
Selective reporting (reporting bias) Low risk We could not locate the protocol of this
study. We could not find the trial registra-
tion number of the study. The outcomes
mentioned in the methods were reported
in the results
Other bias Unclear risk Sources of funding: funding agencies had
no role in views and opinions mentioned
in the study
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Sazawal 1998
Methods Double-blind RCT in which the loss of follow-up was less than 2% The study was
conducted in a low socioeconomic population of urban India
Participants Children, 6 to 35 months of age, presenting to a community-based clinic for acute
diarrhoea and before enrolment, a parent of the child was given an explanation of the
study and written informed consent was obtained. The baseline characteristics for the
child-periods included in the analysis were similar between the two groups. The zinc
group had 298 participants and the placebo one had 311
Interventions Children were randomised to receive either zinc or placebo in a liquid preparation
containing vitamins A (800 units), B1 (0.6 mg), B2 (0.5 mg), B6 (0.5 mg), D3 (100 IU)
, and E (3 mg) and niacinamide (10 mg); the zinc preparation contained zinc gluconate
(10 mg elemental zinc). The liquid preparation 5 mL was given daily for 6 months to
all enrolled children; during diarrhoeal illness this was increased to 10 mL to provide for
excess zinc losses
Outcomes Incidence and prevalence of ALRI. ALRI was diagnosed as using WHO criteria for
respiratory disease episodes based on fast breathing alone
ALRI was also defined as child having cough and at least one assessment documenting:
a) an elevated respiratory rate more than the age-specific value on both 1-minute esti-
mations; and b) a recorded temperature of more than 101°F or lower chest indrawing
Notes Funding: This work was supported by grants from theWHODiarrheal Disease Control
Program, the Thrasher Research Fund, the Johns Hopkins Family Health and Child
Survival Cooperative Agreement with funding from the US Agency for International
Development and the USNational Institutes of Health (R29 HD34724). The assistance
of Ms Usha Dhingra and Mr Dharminder Kashyap in data management and of Sandoz
India Ltd for providing the supplements is appreciated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation schedules with
permuted blocks of 10 were used for chil-
dren“
Allocation concealment (selection bias) Low risk Quote: ”Supplements were prepared and
coded by Sandoz India Ltd (Mumbai).
Both formulation were liquid preparations,
similar in colour and taste“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”double-blind“; ”The Code, which
was kept by WHO personnel, was not
available to the investigator until the end
of the study; “both formulation were liquid
preparations, similar in colour and taste”
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Sazawal 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusion and attrition rates with their rea-
sons were not described in the study
Selective reporting (reporting bias) Low risk We could not locate the protocol of this
study. We could not find the trial registra-
tion number of the study. The outcomes
mentioned in the methods were reported
in the results
Other bias Unclear risk Sandoz India provided the supplements.
Not clear of their role and other funding
agencies
ALRI: acute lower respiratory infection
IU: international unit
RCT: randomised controlled trial
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adhikari 2016 Wrong participants: included children with recurrent respiratory infections
Baqui 2002 Wrong duration: zinc supplementation was given for 2 weeks
Baqui 2003 Wrong diagnosis: ALRI was diagnosed if the child had reported symptoms of cough or difficulty in breathing
with rapid breathing with or without chest indrawing
Bates 1993 Wrong mode of supplementation: zinc supplement was delivered in a fortified drink
Castillo-Duran 1987 Wrong duration; wrong outcomes: zinc was supplemented for 60 days; did not study effects on diarrhoea or
respiratory illnesses
Chandyo 2010 Wrong duration: duration of intervention was 2 weeks
Feiken 2014 Wrong duration: duration of intervention was 10 days
Larson 2010 Wrong diagnosis: did not use this review’s specific ARI definition
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(Continued)
Lind 2004 Wrong diagnosis: considered ‘cough and fever’ as ALRI outcome
Lira 1998 Wrong intervention and outcomes: infants were recruited and supplemented from birth; short course sup-
plementation was provided; only cough was reported
Long 2006 Wrong outcome: respiratory tract infection outcomes were defined as the occurrence of cough alone, cough
and fever, or cough and rapid respiratory rate as reported by the mother
Malik 2014 Wrong diagnosis: considered “cough or cold with or without fever. ALRI was diagnosed if the child had
symptoms of cough with difficult and/or rapid breathing or chest indrawing as informed by the caregiver” as
ALRI
Mazoomar 2010 Wrong diagnosis: considered caregiver’s report of cough or difficulty in breathing along with rapid breathing
McDonald 2015 Wrong population: infants aged less than 2 months at start of intervention (5 to 7 weeks)
Ninh 1996 Wrong diagnosis: respiratory outcome was cough and fever
Osendarp 2002 Wrong population: Infants were recruited and supplemented from 4 weeks of age
Rahman 2001 Wrong duration: supplementation was given for 2 weeks only
Reul 1997 Wrong diagnosis: respiratory infections were defined as the presence of at least two of the following symptoms:
runny nose, cough, wheezing, difficulty breathing, or fever
Richard 2006 Wrong diagnosis: ALRI was reported by parent as presence of cough and rapid respiration
Rosado 1997 Wrong diagnosis: respiratory illness was presence of runny nose, common cold, sore throat or cough
Roy 1999 Wrong duration: zinc supplementation period was 2 weeks
Sampaio 2013 Wrong diagnosis: study used Brazilian Ministry of Health Criteria as ARI definition
Sanchez 2014 Wrong diagnosis: presence of two or more of the following symptoms as ARI: “Cough, runny nose, shortness
of breath and sore throat two or more days duration”
Sempértegui 1996 Wrong duration: zinc supplementation period was 60 days
Soofi 2013 Wrong diagnosis: definition of ARI: “ Signs (fast breathing, chest indrawing) of acute respiratory illness were
recorded as reported by the mother. An acute respiratory illness episode was defined as a minimum of 2 days
with signs followed by a significant interval of at least 7 days”
Sur 2003 Wrong population: Infants were recruited and supplemented from within 7 days of birth
Taneja 2009 Wrong population: zinc supplementation was given to infants between 2 to 4 weeks and 12 months of age
29Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Tielsch 2007 Wrong diagnosis and population: trial was on children aged 1 to 35 months with data not stratified by age,
ARTI: episodes of acute respiratory illness were defined as one or more consecutive days of fever, cough, or
difficulty breathing, with all three symptoms on at least 1 day during the episode and at least 7 days between
episodes
Umeta 2000 Wrong outcomes: cough was only reported respiratory outcome
Vakili 2009 Wrong population: children included older than review’s specified cut off (78 to 120 months)
ALRI: acute lower respiratory infection
ARI: acute respiratory infection
ARTI: acute respiratory tract infection
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D A T A A N D A N A L Y S E S
Comparison 1. Zinc supplementation vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pneumonia incidence 6 5193 Risk Ratio (Fixed, 95% CI) 0.87 [0.81, 0.94]
1.1 Diagnosis based on age-
specific fast breathing with or
without lower chest indrawing
4 1932 Risk Ratio (Fixed, 95% CI) 0.95 [0.86, 1.06]
1.2 Diagnosis based age-
specific fast breathing and
confirmed by chest examination
or chest radiograph
4 3261 Risk Ratio (Fixed, 95% CI) 0.79 [0.71, 0.88]
2 Pneumonia prevalence 1 609 Risk Ratio (Fixed, 95% CI) 0.59 [0.35, 0.99]
Analysis 1.1. Comparison 1 Zinc supplementation vs placebo, Outcome 1 Pneumonia incidence.
Review: Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months
Comparison: 1 Zinc supplementation vs placebo
Outcome: 1 Pneumonia incidence
Study or subgroup Favours experimental Placebo log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Diagnosis based on age-specific fast breathing with or without lower chest indrawing
Bhandari 2002 621 621 -0.0202 (0.067) 32.7 % 0.98 [ 0.86, 1.12 ]
Luabeya 2007 113 113 0.191 (0.358) 1.1 % 1.21 [ 0.60, 2.44 ]
Penny 2004 80 79 -0.128 (0.131) 8.6 % 0.88 [ 0.68, 1.14 ]
Sazawal 1998 149 156 -0.117 (0.137) 7.8 % 0.89 [ 0.68, 1.16 ]
Subtotal (95% CI) 963 969 50.3 % 0.95 [ 0.86, 1.06 ]
Heterogeneity: Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Diagnosis based age-specific fast breathing and confirmed by chest examination or chest radiograph
Bhandari 2002 620 620 -0.301 (0.142) 7.3 % 0.74 [ 0.56, 0.98 ]
Bobat 2005 (1) 46 50 -0.288 (0.158) 5.9 % 0.75 [ 0.55, 1.02 ]
Brooks 2005 809 812 -0.1863 (0.0655) 34.3 % 0.83 [ 0.73, 0.94 ]
0.01 0.1 1 10 100
Favours zinc Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Favours experimental Placebo log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Sazawal 1998 149 155 -0.5798 (0.2546) 2.3 % 0.56 [ 0.34, 0.92 ]
Subtotal (95% CI) 1624 1637 49.7 % 0.79 [ 0.71, 0.88 ]
Heterogeneity: Chi2 = 2.71, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
Total (95% CI) 2587 2606 100.0 % 0.87 [ 0.81, 0.94 ]
Heterogeneity: Chi2 = 9.74, df = 7 (P = 0.20); I2 =28%
Test for overall effect: Z = 3.66 (P = 0.00025)
Test for subgroup differences: Chi2 = 5.78, df = 1 (P = 0.02), I2 =83%
0.01 0.1 1 10 100
Favours zinc Favours placebo
(1) Children with HIV
Analysis 1.2. Comparison 1 Zinc supplementation vs placebo, Outcome 2 Pneumonia prevalence.
Review: Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months
Comparison: 1 Zinc supplementation vs placebo
Outcome: 2 Pneumonia prevalence
Study or subgroup Zinc Placebo log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Sazawal 1998 298 311 -0.528 (0.266) 100.0 % 0.59 [ 0.35, 0.99 ]
Total (95% CI) 298 311 100.0 % 0.59 [ 0.35, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours zinc Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Zinc supplement schedule and duration
Study Supplement Schedule Duration Surveillance
Zinc Control
Bhandari 2002 Zinc gluconate
10 mg
Both groups vitamin
A
Daily 4 months Once weekly
Bobat 2005 Zinc sulphate
10 mg
Placebo Daily 6 months Every 2 weeks
Brooks 2005 Zinc acetate 35 mg
to infants
70 mg to children
aged > 12 months
Placebo Weekly 12 months Once weekly
Luabeya 2007 Zinc gluconate
10 mg
Both groups vitamin
A
Daily (Continued until 24
months of age)
Once weekly
Penny 2004 Zinc gluconate
10 mg
Placebo Daily 6 months Once weekly
Sazawal 1998 Zinc gluconate
10 mg
Placebo Daily 4 months Every 5th day
A P P E N D I C E S
Appendix 1. Previous search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue 2), which contains
the Acute Respiratory Infections Group’s Specialised Register, MEDLINE (1966 to January Week 2, 2010), Embase (1974 to January
2010) and LILACS (1985 to January 2010).
We used the following search strategy to search MEDLINE and CENTRAL. The search strategy incorporates the search strategy
devised by Boluyt 2008 to identify child studies. Due to the small number of search results we chose not to use a search filter to identify
randomised trials. We adapted the search strategy to search Embase (see Appendix 2) and LILACS (see Appendix 3).
MEDLINE (Ovid)
1 exp Pneumonia/
2 pneumon*.tw.
3 lower respiratory tract infection*.tw.
4 lower respiratory infection*.tw.
5 lrti.tw.
6 or/1-5
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7 Zinc/
8 (zinc or zn).tw,nm.
9 or/7-8
10 exp Infant/
11 (infant* or infancy or newborn* or baby* or babies or neonat* or preterm* or prematur*).tw.
12 exp Child/
13 (child* or schoolchild* or school age* or preschool* or kid or kids or toddler*).tw.
14 Adolescent/
15 (adoles* or teen* or boy* or girl*).tw.
16 Minors/
17 Puberty/
18 (minor* or pubert* or pubescen*).tw.
19 exp Pediatrics/
20 (pediatric* or pediatric*).tw.
21 exp Schools/
22 (nursery school* or kindergar* or primary school* or secondary school* or elementary school* or high school* or highschool*).tw.
23 or/10-22
24 6 and 9 and 23
Embase search strategy
14. #5 AND #9 AND #13
13. #10 OR #11 OR #12
12. child*:ab,ti OR schoolchild*:ab,ti OR preschool*:ab,ti OR kid:ab,ti OR kids:ab,ti OR toddler*:ab,ti OR pediatric*:ab,ti OR
paediatric*:ab,ti OR kindergar*:ab,ti OR (school* NEAR/2 (nursery OR primary OR elementary OR age*)):ab,ti
11. infant*:ab,ti OR infancy:ab,ti OR newborn*:ab,ti OR baby*:ab,ti OR babies:ab,ti OR neonat*:ab,ti
OR preterm*:ab,ti OR prematur*:ab,ti
10. ’infant’/exp OR ’child’/exp OR ’pediatrics’/exp OR ’school’/exp
9. #6 OR #7 OR #8
8. zinc:ab,ti OR zn:ab,ti
7. ’gluconate zinc’/exp
6. ’zinc’/exp
5. #1 OR #2 OR #3 OR #4
4. ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR
’lower respiratory infection’:ab,ti OR ’lower respiratory infections’:ab,ti OR lrti:ab,ti
3. ’lower respiratory tract infection’/de
2. pneumon*:ab,ti
1. ’pneumonia’/exp
LILACS search strategy
pneumon$ or namonia or pulmonia or neumonia [Words] and zinc$ or cinc [Words]
“PNEUMONIA” [Subject descriptor] and “ZINC” [Subject descriptor]
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Appendix 2. MEDLINE (Ovid) search strategy
1 exp Pneumonia/
2 (pneumon* or bronchopneumon* or pleuropneumon*).tw.
3 ((respiratory tract infect* or respiratory infect*) adj3 lower).tw.
4 (lower respiratory adj3 infect*).tw.
5 lrti.tw.
6 or/1-5
7 Zinc/
8 (zinc* or zn).tw,nm.
9 Dietary Supplements/
10 trace elements/ or zinc/
11 Micronutrients/
12 exp Zinc Compounds/
13 ((essential or trace) adj1 (mineral* or nutrient*)).tw.
14 micronutrient*.tw.
15 or/7-14
16 6 and 15
Appendix 3. Embase.com search strategy
#24 #15 AND #23
#23 #18 NOT #22
#22 #19 NOT #21
#21 #19 AND #20
#20 ’human’/de AND [embase]/lim
#19 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#18 #16 OR #17
#17 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#16 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#15 #6 AND #14
#14 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#13 micronutrient*:ab,ti
#12 ((essential OR trace) NEAR/1 (mineral* OR nutrient*)):ab,ti
#11 ’zinc derivative’/de
#10 ’trace element’/exp
#9 ’diet supplementation’/de
#8 zinc*:ab,ti OR zn:ab,ti
#7 ’zinc’/de
#6 #1 OR #2 OR #3 OR #4 OR #5
#5 lrti:ab,ti
#4 ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR ’lower respiratory infection’:ab,ti OR ’lower
respiratory infections’:ab,ti
#3 ’lower respiratory tract infection’/de
#2 pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti
#1 ’pneumonia’/exp
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Appendix 4. LILACS (Virtual Health Library) search strategy
> Search > (MH:pneumonia OR pneumon$ OR Neumonía OR MH:C08.381.677$ OR MH:C08.730.610$ OR Pulmonía OR
Bronchopneumonia OR Bronconeumonía OR Broncopneumonia OR Pleuropneumonia OR Pleuroneumonía OR MH:“Respiratory
Tract Infections” OR “Infecciones del Sistema Respiratorio” OR “Infecções Respiratórias” OR “lower respiratory infection” OR “lower
respiratory infections” OR “lower respiratory tract infection” OR “lower respiratory tract infections” OR lrti) AND (MH:zinc OR zinc
OR zinco OR zn OR MH:“Zinc Compounds” OR MH:D01.975$ OR MH:“Dietary Supplements” OR “Suplementos Dietéticos”
OR “Suplementos Dietéticos” OR MH:“Trace Elements” OR Oligoelementos OR MH:Micronutrients OR Micronutrientes)
Appendix 5. CINAHL (EBSCO) search strategy
S23 S13 and S22
S22 S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S21 (MH “Quantitative Studies”)
S20 TI placebo* OR AB placebo*
S19 (MH “Placebos”)
S18 TI random* OR AB random*
S17 TI ((singl* or doubl* or tripl* or trebl*) N1 (blind* or mask*)) OR AB ((singl* or doubl* or tripl* or trebl*) N1 (blind* or mask*))
S16 TI clinic* trial* OR AB clinic* trial*
S15 PT clinical trial Search modes -
S14 (MH “Clinical Trials+”)
S13 S4 and S12
S12 S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TI micronutrient* OR AB micronutrient*
S10 TI ((essential or trace) N1 (mineral* or nutrient*)) OR AB ((essential or trace) N1 (mineral* or nutrient*))
S9 (MH “Micronutrients”)
S8 (MH “Trace Elements”)
S7 (MH “Dietary Supplements”)
S6 TI (zinc* or zn) OR AB (zinc* or zn)
S5 (MH “Zinc”) OR (MH “Zinc Compounds+”)
S4 S1 or S2 or S3
S3 TI (lower respiratory tract infect* or lower respiratory infect* or lrti) OR AB (lower respiratory tract infect* or lower respiratory
infect* or lrti)
S2 TI (pneumon* or bronchopneumon* or pleuropneumon*) OR AB (pneumon* or bronchopneumon* or pleuropneumon*)
S1 (MH “Pneumonia+”)
Appendix 6. Web of Science (Thomson Reuters)
Topic=(pneumonia or bronchopneumonia or pleuropneumonia) AND Topic=(zinc)
Refined by: Topic=(random* or placebo* or clinical trial* or double blind*)
Timespan=All Years. Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC.
Lemmatization=Off
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F E E D B A C K
Feedback comment by Joseph L. Mathew, 10 February 2011
Summary
Please note the following feedback.
1. The forest plot in Analysis 1.1 shows that participants in the trial by Bhandari et al, have been split to present two different outcomes.
Half the participants in each arm are included for the outcome “Diagnosis based on age-specific fast breathing with or without lower
chest indrawing” and half for the outcome “Diagnosis based age-specific fast breathing AND confirmed by chest examination or chest
radiograph”. Both outcomes have been presented as subgroup analysis in the same forest plot; although the trial report mentions that
both outcomes were evaluated in all participants. Please confirm whether the procedure adopted in this review is standard practice; and
the purpose of doing this.
Answer: We presented the findings after dividing the participants equally in the four cells so that participants do not repeat across
analysis. The number of participants were 1241 in each group and we divided them as 620/621 for each of the four cells).
2. A similar adjustment seems to have been made with the participants in the trial by Sazawal et al.
Answer: Adjusted
3. The reference section mentions three citations under Sazawal 1998a; and one under Sazawal 1998b. The third citation in Sazawal
1998a is the same as Sazawal 1998b. Further, none of the citations reports 3300 participants in the trial; whereas this is the number
included in the meta-analysis. Sazawal’s 1995 publication in the New England Journal of Medicine mentions 937 participants; while
the 1998 publication in Pediatrics reported 609 participants. Please confirm the basis for using the numbers in the meta-analysis.
Answer: Those were the two parts of the same study. We have now merged it and presented it as one study.
4. Themeta-analysis has pooled data from childrenwithHIV infection, along with otherwise healthy children.While it seems reasonable
to pool children with unknown HIV status with otherwise healthy children, it would be better to analyse HIV infected children
separately since pneumonia in immuno-compromised children could be quite different from otherwise healthy children.
Answer: In the text only, we presented the results on removing Bobat trial as well.
Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
We thank Dr Mathew for these comments.
Contributors
Joseph L. Mathew
WH A T ’ S N E W
Date Event Description
25 January 2017 Amended Minor data transcription error corrected
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H I S T O R Y
Date Event Description
26 October 2015 New search has been performed A new review author joined us to update this review.We
excluded 11 new trials (Adhikari 2016; Chandyo 2010;
Feiken 2014; Larson 2010; Malik 2014; Mazoomar
2010; McDonald 2015; Sampaio 2013; Sanchez 2014;
Soofi 2013; Vakili 2009).
26 October 2015 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
26 October 2015 New search has been performed Searches updated,
8 May 2013 New search has been performed Searches conducted
10 February 2012 Amended Authors replied to Feedback comment
8 August 2011 Feedback has been incorporated Feedback added to review.
C O N T R I B U T I O N S O F A U T H O R S
Zohra S Lassi (ZSL) entered data, created the comparisons, carried out the analysis and wrote the text of the review under the guidance
of Dr Zulfiqar A Bhutta (ZAB). Anoosh Moin (AM) took part in screening results and updating the review.
D E C L A R A T I O N S O F I N T E R E S T
Zohra S Lassi: none known.
Anoosh Moin: none known.
Zulfiqar A Bhutta: none known.
S O U R C E S O F S U P P O R T
Internal sources
• The Aga Khan University, Pakistan.
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added mandatory sections such as subgroup analysis and sensitivity analysis for this update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Gluconates [administration & dosage]; Pneumonia [epidemiology; ∗prevention & control]; Randomized Controlled Trials as Topic;
Zinc Acetate [administration & dosage]; Zinc Compounds [∗administration & dosage]; Zinc Sulfate [administration & dosage]
MeSH check words
Child, Preschool; Humans; Infant
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